Replies to post #41281 on Amarin Corp Plc (AMRN)

[couldbebetter]

The JELIS study shows EPA has beneficial results in humans. The question is how much a benefit will Reduce-It show. Anything at 15% or higher and AMRN should be golden. Given that our study has very sick people in it I think if Vascepa is effective it will show in the results...especially when you consider the very high dose of EPA used. My guess as to why this dosage is that it is better to overtreat rather than undertreat. As safe as EPA is at these strong dosages you will have some initial side effects as the body adjusts to the strong dosae. I think JL stated that patients should not start at the full dose but work their way up to it over the course of a month. 4 grams EPA is very powerful. The JELIS study only used 1.8 grams. That alone is a huge difference. Again, I think AMRN is going for the best possible reults here...i do hope it works out that way.

[Biobillionair]

Rosemount---

There will be no slow rise in Amarin stock shares. Wall Street won't touch Amarin with a ten foot pole until it knows Officers didn't lie about Anchor SPA and other CVOT. All eye's on lawsuit...if it gets dropped or dismissed then the big boys could be more assured there're not being played for fools. Only science nerds, stuck retail and momentum traders for now.

JMO
BB

[sts66]

Obviously the largest part of the market does not believe Reduce-It will bear fruit or the readout is still too far in the future for people to stake out positions that would raise the pps.

It's your 2nd thought that is likely the culprit in our stagnant pps - if you were a large fund, would you put up big bucks that will earn you no money for at least another year, or put that money to work now, and presumably still be able to pick up cheap AMRN shares closer to interim results, assuming you believe it will be a success? Everyone here that owns stock will have at least 2-4 yrs of dead red money on their hands by the time R-IT interim is released - we could have earned a lot of money putting it to use in other stocks or funds during that period of time.

[zumantu]

The other factor in reduced visibility to V effectiveness in Reduce It comes from the fact it's a preventative effect, less than curative. In trials of very sick subjects, HepC, Cancer etc. patients can chat up their results and data can be leaked. But in CVD, nobody is going to go public with " I didn't have a heart attack"!

Hence visibility via leaks is highly unlikely....